Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1639 1645 1654 1658 1676
This examiner grants 59% of resolved cases
Amber D. Steele serves as a patent examiner in Tech Center 1600 and Art Unit 1627. She has overseen 824 resolved cases. The examiner demonstrates an allowance rate of 58.9 percent, which indicates the proportion of applications that successfully reach issuance. This rate provides a clear expectation for practitioners regarding the probability of a grant when their cases are assigned to this examiner.
The median time to allowance is 1252 days. This duration defines the typical timeframe for the prosecution cycle for successful applications. When managing a portfolio, practitioners can use this 1252 day figure to estimate the period required to navigate the examination process in Art Unit 1627. The 824 resolved cases provide a stable basis for this temporal metric.
The data also reveals an interview lift of 9.3 percent. This positive lift indicates that conducting an interview with the examiner correlates with an increased likelihood of securing an allowance. Practitioners can use this 9.3 percent figure to evaluate the potential benefits of direct communication. These combined metrics offer a data-grounded view of the examination environment for applicants in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18404131 | MANP Analogues | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17768537 | Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17778306 | POLYPEPTIDE INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY AND USES THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 18564739 | Substrate-specific adhesive peptides | Non-Final OA | HENKEL AG & CO. KGAA |
| 18265523 | SCG2 NEUROPEPTIDES AND USES THEREOF | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18580971 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES, COMPRISING STC-1 OR DERIVATIVE THEREOF | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18872790 | PREVENTING ALU SINES-MEDIATED PATHOLOGIES | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18533699 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | Non-Final OA | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 17296795 | PEPTIDE LIGANDS FOR CAPTURE OF HOST CELL PROTEINS | Final Rejection | North Carolina State University |
| 18265883 | METHODS OF MAKING WATER-SOLUBLE PROTEIN FORMED IN A BACTERIAL EXPRESSION SYSTEM, COMPOSITIONS, AND METHODS OF USE THEREOF | Final Rejection | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK |
| 18290740 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | Non-Final OA | OREGON HEALTH & SCIENCE UNIVERSITY |
| 16632226 | COMPOSITIONS AND METHODS COMPRISING SELF-ASSEMBLING PEPTIDE-POLYMER NANOFIBERS FOR SUBLINGUAL IMMUNIZATION | Non-Final OA | Duke University |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | Final Rejection | SENJU PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy